What does Agilent Technologies do?

Agilent provides instruments, software, services and consumables for laboratories in life sciences, diagnostics and applied markets, according to its 10-K for fiscal 2025. It reports three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab (services, consumables, software and lab automation) and Applied Markets.

How much revenue did Agilent make in fiscal 2025?

Net revenue was $6,948 million in fiscal 2025, the year ended October 31, 2025, compared with $6,510 million in fiscal 2024, according to its 10-K. Net income was $1,303 million, or $4.57 per diluted share.

When does Agilent's fiscal year end?

Agilent's fiscal year ends October 31. Fiscal 2025 ran to October 31, 2025, and the quarter ended July 31, 2026 is the third quarter of fiscal 2026.

How much of Agilent's revenue comes from China?

Its 10-K reports fiscal 2025 net revenue of $1,224 million from China (including Hong Kong), against $2,342 million from the United States and $3,382 million from the rest of the world.

What were Agilent's latest quarterly results?

For the quarter ended July 31, 2026, its 10-Q (unaudited) reports net revenue of $1,878 million and net income of $362 million, or $1.28 per diluted share. In its August 26, 2026 press release Agilent reported non-GAAP EPS, a non-GAAP measure, of $1.62 for the quarter.

What is Agilent's fiscal 2026 outlook?

In its August 26, 2026 press release Agilent said fiscal year 2026 revenue is now expected in the range of $7.49 billion to $7.51 billion and non-GAAP EPS in the range of $6.18 to $6.21, and fourth-quarter 2026 revenue in the range of $1.98 billion to $2.0 billion. These are the company's own projections, not reported results.

What companies has Agilent acquired recently?

It acquired BIOVECTRA in September 2024 for total consideration of $915 million in cash, expanding its contract development and manufacturing organization (10-K), and BC Midco I, Inc. (Biocare) on June 24, 2026 for a net consideration paid of $950 million, expanding its pathology portfolio (10-Q for the quarter ended July 31, 2026).

Does Agilent pay a dividend?

Yes. Cash dividends of $0.992 per share were declared and paid in fiscal 2025, and on November 19, 2025 it declared a quarterly dividend of $0.255 per share (10-K). It paid $0.765 per share in the nine months ended July 31, 2026 (10-Q). The 10-Q says the timing and amounts of future dividends are subject to approval by its board.

Does Agilent buy back its own shares?

Yes. In fiscal 2025 it repurchased 3.0 million shares for $374 million under its 2023 program and 381,670 shares for $51 million under its 2024 program, excluding excise taxes (10-K). At July 31, 2026 it had remaining authorization of approximately $1,654 million (10-Q).

DalsnaFinance Account

Agilent Technologies $A

Health Care · Life Sciences Tools & Services · NYSE/NASDAQ

Profile updated Oct 15, 2026 Figures as of Oct 13, 2026

S&P 500 Russell 1000 California

Create a scorecard

$177.34

+4.33 (+2.50%)

As of Oct 21, 2026, 11:10 AM EDT

Price history

Loading chart…

Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Aug 27, 2026, the first target we tracked for A.

Key facts

52-week range (closes): $110.24 – $175.21 Lowest close Mar 27, 2026, highest Sep 28, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
Fiscal year ends: October Fiscal 2025 ended Oct 31, 2025, from SEC filings
In the S&P 500 since: Jun 5, 2000 · All S&P 500 changes
Analyst coverage: 1 open price target from 1 firm: RBC Capital Markets Approved targets tracked here; see the analyst section below

Agilent Technologies (A) is trading up at $177.34 (+2.50%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Analyst price targets on A

One firm's current price target on Agilent Technologies: $185 — 4% above the current $177. Each is tracked to its date and scored the same way a member's call is.

RBC Capital Markets $158 → $185 by Aug 2027 Outperform Aug 27, 2026 via Investing.com · RBC Capital Markets's track record

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Agilent Technologies revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)

Agilent Technologies annual financial statements
	FY2016Oct 2016	FY2017Oct 2017	FY2018Oct 2018	FY2019Oct 2019	FY2020Oct 2020	FY2021Oct 2021	FY2022Oct 2022	FY2023Oct 2023	FY2024Oct 2024	FY2025Oct 2025
Income statement
Revenue	$4.20B	$4.47B	$4.91B	$5.16B	$5.34B	$6.32B	$6.85B	$6.83B	$6.51B	$6.95B
Growth (year over year)	+4.1%	+6.4%	+9.9%	+5.1%	+3.4%	+18.4%	+8.4%	−0.2%	−4.7%	+6.7%
Gross profit	$2.20B	$2.41B	$2.68B	$2.81B	$2.84B	$3.41B	$3.72B	$3.46B	$3.54B	$3.64B
Gross margin	52.3%	53.9%	54.5%	54.3%	53.1%	53.9%	54.4%	50.7%	54.3%	52.4%
Operating income	$615.0M	$807.0M	$904.0M	$941.0M	$846.0M	$1.35B	$1.62B	$1.35B	$1.49B	$1.48B
Operating margin	14.6%	18.0%	18.4%	18.2%	15.8%	21.3%	23.6%	19.8%	22.9%	21.3%
Net income	$462.0M	$684.0M	$316.0M	$1.07B	$719.0M	$1.21B	$1.25B	$1.24B	$1.29B	$1.30B
Net margin	11.0%	15.3%	6.4%	20.7%	13.5%	19.1%	18.3%	18.1%	19.8%	18.8%
EPS (diluted)	$1.40	$2.10	$0.97	$3.37	$2.30	$3.94	$4.18	$4.19	$4.43	$4.57
Balance sheet
Cash and equivalents	$2.29B	$2.68B	$2.25B	$1.38B	$1.44B	$1.48B	$1.05B	$1.59B	$1.33B	$1.79B
Total assets	$7.79B	$8.43B	$8.56B	$9.45B	$9.63B	$10.7B	$10.5B	$10.8B	$11.8B	$12.7B
Total liabilities	$3.55B	$3.59B	$3.96B	$4.70B	$4.75B	$5.32B	$5.23B	$4.92B	$5.95B	$5.99B
Long-term debt	$1.90B	$1.80B	$1.80B	$1.79B	$2.28B	$2.73B	$2.73B	$2.73B	$3.35B	$3.05B
Shareholders' equity	$4.24B	$4.83B	$4.59B	$4.75B	$4.87B	$5.39B	$5.30B	$5.84B	$5.90B	$6.74B
Cash flow
Operating cash flow	$793.0M	$889.0M	$1.09B	$1.02B	$921.0M	$1.49B	$1.31B	$1.77B	$1.75B	$1.56B
Capital expenditure	$139.0M	$176.0M	$177.0M	$155.0M	$119.0M	$188.0M	$291.0M	$298.0M	$378.0M	$407.0M
Free cash flow	$654.0M	$713.0M	$910.0M	$866.0M	$802.0M	$1.30B	$1.02B	$1.47B	$1.37B	$1.15B
Dividends paid	$150.0M	$170.0M	$191.0M	$206.0M	$222.0M	$236.0M	$250.0M	$265.0M	$274.0M	$282.0M
Share buybacks	$434.0M	$194.0M	$422.0M	$723.0M	$469.0M	$788.0M	$1.14B	$575.0M	$1.15B	$425.0M

RevenueNet incomeNet margin (right axis, %)

Agilent Technologies quarterly financial statements
	Q4 FY24^†Oct 2024	Q1 FY25Jan 2025	Q2 FY25Apr 2025	Q3 FY25Jul 2025	Q4 FY25^†Oct 2025	Q1 FY26Jan 2026	Q2 FY26Apr 2026	Q3 FY26Jul 2026
Income statement
Revenue	$1.70B	$1.68B	$1.67B	$1.74B	$1.86B	$1.80B	$1.83B	$1.88B
Growth (year over year)	+0.8%	+1.4%	+6.0%	+10.1%	+9.4%	+7.0%	+10.0%	+8.1%
Gross profit	$916.0M	$899.0M	$866.0M	$888.0M	$990.0M	$946.0M	$990.0M	$1.04B
Gross margin	53.9%	53.5%	51.9%	51.1%	53.2%	52.6%	54.0%	55.5%
Operating income	$408.0M	$376.0M	$300.0M	$360.0M	$443.0M	$353.0M	$399.0M	$444.0M
Operating margin	24.0%	22.4%	18.0%	20.7%	23.8%	19.6%	21.7%	23.6%
Net income	$351.0M	$318.0M	$215.0M	$336.0M	$434.0M	$305.0M	$339.0M	$362.0M
Net margin	20.6%	18.9%	12.9%	19.3%	23.3%	17.0%	18.5%	19.3%
EPS (diluted)	$1.23	$1.11	$0.75	$1.18	$1.53	$1.07	$1.20	$1.28
Balance sheet
Cash and equivalents	$1.33B	$1.47B	$1.49B	$1.53B	$1.79B	$1.76B	$1.81B	$1.76B
Total assets	$11.8B	$11.9B	$12.2B	$12.2B	$12.7B	$12.8B	$13.1B	$14.0B
Total liabilities	$5.95B	$5.89B	$6.02B	$5.86B	$5.99B	$5.91B	$5.94B	$6.60B
Long-term debt	$3.35B	$3.35B	$3.35B	$3.35B	$3.05B	$3.05B	$3.05B	$3.65B
Shareholders' equity	$5.90B	$6.03B	$6.14B	$6.37B	$6.74B	$6.91B	$7.12B	$7.36B
Cash flow
Operating cash flow	$481.0M	$431.0M	$221.0M	$362.0M	$545.0M	$268.0M	$277.0M	$519.0M
Capital expenditure	$93.0M	$97.0M	$114.0M	$103.0M	$93.0M	$93.0M	$76.0M	$80.0M
Free cash flow	$388.0M	$334.0M	$107.0M	$259.0M	$452.0M	$175.0M	$201.0M	$439.0M
Dividends paid	$68.0M	$71.0M	$70.0M	$71.0M	$70.0M	$72.0M	$72.0M	$72.0M
Share buybacks	$335.0M	$90.0M	$165.0M	$85.0M	$85.0M	$152.0M	$65.0M	$78.0M

From Agilent Technologies's 10-K and 10-Q filings with the SEC; its fiscal year ends in October. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Agilent Technologies vs the Health Care sector and the S&P 500

Agilent Technologies's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.

Agilent Technologies compared with the median Health Care company and the median S&P 500 company
Measure	Agilent Technologies	Health Care (59 other S&P 500 companies)	S&P 500 (502 other companies)
Revenue growth, latest fiscal year	+6.7%	+7.2%	+7.0%
Net margin, latest fiscal year	18.8%	12.9%	12.9%
Dividend per share, latest fiscal year	$0.99	$2.48	$2.40
Share price change, 1 year	+20.4%	+20.2%	+6.8%

Agilent Technologies: fiscal year ended October 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 21, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Agilent Technologies included, were fetched between 10:06 and 10:15 ET on October 21, 2026; the 1-year change compares that price with each company's last close on or before October 21, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, dividend per share 32/349, 1-year price change 59/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them; dividend medians are among the 32 sector and 349 S&P 500 companies reporting a per-share dividend. The S&P 500 price figure is the middle company's change, not the index's return.

About Agilent Technologies

Agilent Technologies, Inc. is an American global company headquartered in Santa Clara, California, that provides instruments, software, services, and consumables for laboratories. Agilent was established in 1999 as a spin-off from Hewlett-Packard. The resulting initial public offering of Agilent stock was the largest in the history of Silicon Valley at the time.

Source: Wikipedia — Agilent Technologies

Headquarters: Santa Clara, California From SEC filings, Oct 2026

Company profile

Agilent Technologies, Inc., incorporated in Delaware in May 1999 and with its principal executive offices in Santa Clara, California, describes itself in its annual report for fiscal 2025 (Form 10-K) as a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its fiscal year ends October 31. It reports three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. It employed approximately 18,100 people worldwide as of October 31, 2025 (10-K). Its common stock trades on the NYSE as A.

For fiscal 2025 (the year ended October 31, 2025) the consolidated statements of operations report net revenue of $6,948 million, income from operations of $1,479 million and net income of $1,303 million, or $4.57 per diluted share. The 10-K says net revenue increased 7 percent compared with 2024 and that revenue from the BIOVECTRA acquisition, completed in September 2024 for total consideration of $915 million in cash, contributed approximately 2 percentage points. Net cash provided by operating activities was $1,559 million. At October 31, 2025 total assets were $12,727 million and total stockholders' equity was $6,741 million (10-K).

Pharmaceutical and biopharmaceutical customers are the largest end market: $2,507 million of fiscal 2025 net revenue, followed by chemical and advanced materials at $1,561 million and diagnostics and clinical at $1,029 million. By geography, the 10-K reports fiscal 2025 net revenue of $2,342 million in the United States, $1,224 million in China (including Hong Kong) and $3,382 million in the rest of the world.

According to its 10-Q for the quarter ended July 31, 2026 (unaudited), the third quarter of fiscal 2026, net revenue was $1,878 million for the quarter and $5,511 million for the first nine months, and net income was $362 million for the quarter, or $1.28 per diluted share. On June 24, 2026 Agilent acquired BC Midco I, Inc. (Biocare), which the 10-Q describes as a leading provider of clinical and research solutions, for a net consideration paid of $950 million; Biocare is included in the Life Sciences and Diagnostics Markets segment (10-Q). On June 25, 2026 Agilent closed the sale of $600 million of 4.900% Senior Notes due 2032 (Form 8-K). In its August 26, 2026 press release it said fiscal year 2026 revenue is now expected in the range of $7.49 billion to $7.51 billion and non-GAAP fiscal year 2026 EPS in the range of $6.18 to $6.21 (company projections; the EPS range is non-GAAP).

Padraig McDonnell has served as President and Chief Executive Officer since May 2024, and Adam S. Elinoff has been Chief Financial Officer since November 2025 (10-K). In a Form 8-K filed September 8, 2026 Agilent said Boon Hwee Koh, Chairperson of the Board, retired from the board effective September 4, 2026, and that the board appointed Glenn Boehnlein as a director to fill the vacancy.

Summary sources:¹²³⁴⁵⁶⁷⁸⁹¹⁰

$6,948 million²

Net revenue, fiscal 2025 (year ended October 31, 2025)

$4,944 million²

Products net revenue, fiscal 2025

$2,004 million²

Services and other net revenue, fiscal 2025

$455 million²

Research and development, fiscal 2025

$1,479 million²

Income from operations, fiscal 2025

$1,303 million²

Net income, fiscal 2025

$4.57²

Net income per share, diluted, fiscal 2025

$1,559 million¹¹

Net cash provided by operating activities, fiscal 2025

$0.992¹²

Cash dividends declared per share, fiscal 2025

$1,789 million¹³

Cash and cash equivalents, October 31, 2025

$12,727 million¹³

Total assets, October 31, 2025

$3,050 million¹³

Long-term debt, October 31, 2025

$6,741 million¹³

Total stockholders' equity, October 31, 2025

18,100¹

Employees, October 31, 2025 (approximate)

$1,878 million⁶

Net revenue, quarter ended July 31, 2026 (unaudited)

$5,511 million⁶

Net revenue, nine months ended July 31, 2026 (unaudited)

$362 million⁶

Net income, quarter ended July 31, 2026 (unaudited)

$1.28⁶

Net income per share, diluted, quarter ended July 31, 2026 (unaudited)

$1.62⁹

Non-GAAP EPS, quarter ended July 31, 2026 (non-GAAP, as reported by Agilent)

$1,758 million¹⁴

Cash and cash equivalents, July 31, 2026 (unaudited)

$3,645 million¹⁴

Long-term debt, July 31, 2026 (unaudited)

281,928,854¹⁵

Common shares outstanding, August 26, 2026 (10-Q cover)

$950 million⁷

Biocare acquisition, net consideration paid (completed June 24, 2026)

$7.49 billion to $7.51 billion⁹

Fiscal year 2026 revenue outlook (company projection, as of August 26, 2026)

$6.18 to $6.21⁹

Fiscal year 2026 EPS outlook (company projection, non-GAAP, as of August 26, 2026)

Revenue by fiscal year, as reported in 10-K

Fiscal year	Revenue (as reported in 10-K)	Reported as	Filed
2021	$6,319 million¹⁶	Form 10-K for fiscal year 2021 (year ended October 31, 2021), net revenue, in millions as filed	Dec 17, 2021
2022	$6,848 million¹⁷	Form 10-K for fiscal year 2022 (year ended October 31, 2022), net revenue, in millions as filed	Dec 21, 2022
2023	$6,833 million¹⁸	Form 10-K for fiscal year 2023 (year ended October 31, 2023), net revenue, in millions as filed	Dec 20, 2023
2024	$6,510 million¹⁹	Form 10-K for fiscal year 2024 (year ended October 31, 2024), net revenue, in millions as filed	Dec 20, 2024
2025	$6,948 million²	Form 10-K for fiscal year 2025 (year ended October 31, 2025), net revenue, in millions as filed	Dec 22, 2025

Products

Life Sciences and Diagnostics Markets

Name	Released	What it is
Liquid chromatography	—	Liquid, high-performance and ultra-high performance liquid chromatographs, used to separate molecules of a liquid mixture to determine the quantity and identity of the molecules present. The 10-K says the portfolio is largely modular and configurable as analytical and preparative systems.¹
Liquid chromatography mass spectrometry	—	Instruments built around four main analyzer types: single quadrupole, triple quadrupole, time-of-flight and quadrupole time-of-flight (10-K, Item 1).¹
CoverStainer and Artisan product families	—	Pathology products that target primary cancer diagnostics through hematoxylin and eosin staining as well as special stains (10-K, Item 1).¹
Dako Omnis and Autostainer immunohistochemistry solutions	—	Immunohistochemistry solutions which, with instant quality fluorescence in situ hybridization technologies, provide advanced tumor typing through investigation of protein and gene expression. The 10-K says these products also include companion diagnostic tests.¹
Bulk antibodies	—	Antibodies offered as raw materials, with a range of associated assay development services, to in vitro diagnostics manufacturers, biotechnology and pharmaceutical companies (10-K, Item 1).¹
Clinical flow cytometry reagents	—	Reagents and kits provided directly to clinical laboratories working in routine cancer diagnostics, with particular focus on blood cancers (10-K, Item 1).¹
Cell analysis portfolio	—	Including cell analysis plate-based assays, flow cytometer, real-time cell analyzer, microplate reader, cell imaging system and related consumables, used to study cell signaling pathways and general cell function and behavior (10-K, Item 1).¹
Seahorse, xCELLigence, Novocyte and BioTek platform technologies	—	Used stand-alone and with mass spectrometry to understand cellular physiology and interactions in normal and diseased states. The 10-K says xCELLigence and Novocyte can be used to characterize and quantify immune cell response.¹
Companion diagnostics	—	Potential pharmacodiagnostics developed with several major pharmaceutical companies, which may be used to identify patients most likely to benefit from a specific targeted therapy; support runs from early pre-clinical through commercial launch (10-K, Item 1).¹
Next-generation sequencing target enrichment portfolio	—	Enables customers to select specific target regions of the genome for sequencing; customers can customize the products for their regions of interest, including gene panels and exome designs (10-K, Item 1).¹
Comparative genomic hybridization microarrays	—	Microarrays mostly used by customers in cytogenetic laboratories to detect genome-wide copy number alterations (10-K, Item 1).¹
Nucleic acid solutions (oligonucleotide CDMO)	—	Mid to large scale production of synthesized oligonucleotide active pharmaceutical ingredients under pharmaceutical good manufacturing practices conditions, taking customers' oligo drug candidates from clinical trials to commercial scale volumes (10-K, Item 1).¹
BIOVECTRA	—	Part of the specialty CDMO offering; the 10-K says its capabilities include microbial fermentation, bioreagents, highly potent active pharmaceutical ingredients, peptide purification and biomanufacturing in several nucleic acid modalities.¹
Automated electrophoresis (biomolecular analysis)	—	Workflow solutions, including instruments, consumables and software, for quality control analysis of nucleic acid samples, used to check sample integrity before analysis such as next-generation sequencing (10-K, Item 1).¹

Agilent CrossLab

Name	Released	What it is
Services and support	—	Startup, operational, educational and compliance support services, including maintenance, troubleshooting, repair and training for its instrument hardware and software, and enterprise services such as lab supply management, asset management, procurement and informatics (10-K, Item 1).¹
Chemistries and supplies	—	Including solid phase extraction and filtration products, self-manufactured gas and liquid chromatography columns, chemical standards, and instrument parts and supplies. The 10-K says most of the consumables portfolio is vendor neutral.¹
OpenLab Laboratory Software Suite	—	Described in the 10-K as a scalable, open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise.¹
Software and informatics	—	Software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management, which the 10-K says facilitates compliant instrument use in pharmaceutical quality assurance and quality control.¹
Laboratory automation	—	Automated sample preparation solutions including liquid handling, plate management, consumables and scheduling software, ranging from standalone instrumentation to bench-top automation (10-K, Item 1).¹

Applied Markets

Name	Released	What it is
Gas chromatography	—	Laboratory and portable gas chromatographs, custom or standard analyzers configured for specific chemical analysis applications, and related software, accessories and consumables (10-K, Item 1).¹
Gas chromatography mass spectrometry	—	Instruments built around three main analyzer types: single quadrupole, triple quadrupole and quadrupole time-of-flight (10-K, Item 1).¹
Spectroscopy	—	Including atomic absorption, microwave plasma-atomic emission, inductively coupled plasma optical emission and mass spectrometry, fluorescence, ultraviolet-visible, fourier transform infrared, near-infrared and raman instruments, and sample automation products (10-K, Item 1).¹
Vacuum technology	—	Including high and ultra-high vacuum pumps, primary vacuum pumps, vacuum instrumentation and components, and helium mass spectrometry and helium-sensing leak detection instruments, mostly sold to OEMs and government and research organizations (10-K, Item 1).¹
Remarketed instruments	—	Certified pre-owned instruments that Agilent refurbishes and resells to value-oriented customers (10-K, Item 1).¹

Segments and products

Life Sciences and Diagnostics Markets: The 10-K says the segment is comprised of seven areas of activity, covering liquid chromatography and liquid chromatography mass spectrometry systems, cell analysis, contract development and manufacturing (CDMO), pathology, companion diagnostics, genomics and biomolecular analysis, and sells primarily into the pharmaceutical and biopharmaceutical, diagnostics and clinical and academic and government markets. It had approximately 22,200 customers in fiscal year 2025 (10-K, Item 1).¹
Agilent CrossLab: The 10-K says the segment spans the entire lab with its extensive services and consumables portfolio, in addition to software and laboratory automation solutions, serving customer needs across end-markets and applications. It had approximately 59,700 customers in fiscal year 2025 (10-K, Item 1).¹
Applied Markets: The 10-K says the segment provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Its key end markets include chemicals and advanced materials, environmental and forensics, and food. It had approximately 17,200 customers in fiscal year 2025 (10-K, Item 1).¹
Segment results, fiscal 2023 to 2025: Net revenue as filed: Life Sciences and Diagnostics Markets $2,726 million in fiscal 2025, $2,466 million in 2024 and $2,780 million in 2023; Agilent CrossLab $2,908 million, $2,747 million and $2,656 million; Applied Markets $1,314 million, $1,297 million and $1,397 million. Segment income from operations in fiscal 2025 was $536 million, $946 million and $301 million respectively (10-K, segment note).²⁰
Segment results, quarter ended July 31, 2026: Net revenue as filed (unaudited): Life Sciences and Diagnostics Markets $746 million, Agilent CrossLab $786 million and Applied Markets $346 million; segment income from operations $176 million, $270 million and $86 million respectively (10-Q, segment note).²¹
Revenue by end market, fiscal 2025: Net revenue as filed: pharmaceutical and biopharmaceutical $2,507 million; chemical and advanced materials $1,561 million; diagnostics and clinical $1,029 million; environmental and forensics $674 million; food $637 million; academia and government $540 million (10-K, revenue note).³

Risks

International sales and China: Agilent says it anticipates that revenue from international operations will continue to represent a majority of its total revenue, exposing it to economic, political and foreign currency risks, including political and trade uncertainties in the greater China region (10-K, Item 1A).¹
Tariffs and government policy: The 10-K says recent and dynamic government rule making and policy changes could increase its costs and affect its markets and customers, and that future tariffs and tariffs already implemented could have a negative impact on its business (10-K, Item 1A).¹
Customer spending: Demand for some of its products and services depends on the capital spending policies and research and development budgets of its customers, which include pharmaceutical companies, laboratories, universities and healthcare providers, and its results could be harmed if the markets it sells into decline (10-K, Item 1A).¹
Competition and new products: Agilent says the life sciences industry is intensely competitive and has been subject to increasing consolidation, and that its results could suffer if it does not introduce successful new products and services in a timely manner (10-K, Item 1A).¹
Acquisitions and integration: The 10-K says its acquisitions, strategic investments and alliances, joint ventures, exiting of businesses and divestitures may result in financial results that are different than expected, and that integrating the operations of acquired businesses could be a difficult, costly and time-consuming process (10-K, Item 1A).¹
Debt and regulation: As of October 31, 2025 Agilent had approximately $3.4 billion in outstanding indebtedness, which it says could adversely affect its financial condition. Some products are subject to extensive regulation by the Food and Drug Administration and similar foreign regulators (10-K, Item 1A).¹

Frequently asked questions

What does Agilent Technologies do?: Agilent provides instruments, software, services and consumables for laboratories in life sciences, diagnostics and applied markets, according to its 10-K for fiscal 2025. It reports three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab (services, consumables, software and lab automation) and Applied Markets.
How much revenue did Agilent make in fiscal 2025?: Net revenue was $6,948 million in fiscal 2025, the year ended October 31, 2025, compared with $6,510 million in fiscal 2024, according to its 10-K. Net income was $1,303 million, or $4.57 per diluted share.
When does Agilent's fiscal year end?: Agilent's fiscal year ends October 31. Fiscal 2025 ran to October 31, 2025, and the quarter ended July 31, 2026 is the third quarter of fiscal 2026.
Who are Agilent's biggest customers by market?: Pharmaceutical and biopharmaceutical customers were the largest end market, with $2,507 million of fiscal 2025 net revenue, followed by chemical and advanced materials ($1,561 million) and diagnostics and clinical ($1,029 million), according to its 10-K.
How much of Agilent's revenue comes from China?: Its 10-K reports fiscal 2025 net revenue of $1,224 million from China (including Hong Kong), against $2,342 million from the United States and $3,382 million from the rest of the world.
What were Agilent's latest quarterly results?: For the quarter ended July 31, 2026, its 10-Q (unaudited) reports net revenue of $1,878 million and net income of $362 million, or $1.28 per diluted share. In its August 26, 2026 press release Agilent reported non-GAAP EPS, a non-GAAP measure, of $1.62 for the quarter.
What is Agilent's fiscal 2026 outlook?: In its August 26, 2026 press release Agilent said fiscal year 2026 revenue is now expected in the range of $7.49 billion to $7.51 billion and non-GAAP EPS in the range of $6.18 to $6.21, and fourth-quarter 2026 revenue in the range of $1.98 billion to $2.0 billion. These are the company's own projections, not reported results.
What companies has Agilent acquired recently?: It acquired BIOVECTRA in September 2024 for total consideration of $915 million in cash, expanding its contract development and manufacturing organization (10-K), and BC Midco I, Inc. (Biocare) on June 24, 2026 for a net consideration paid of $950 million, expanding its pathology portfolio (10-Q for the quarter ended July 31, 2026).
Does Agilent pay a dividend?: Yes. Cash dividends of $0.992 per share were declared and paid in fiscal 2025, and on November 19, 2025 it declared a quarterly dividend of $0.255 per share (10-K). It paid $0.765 per share in the nine months ended July 31, 2026 (10-Q). The 10-Q says the timing and amounts of future dividends are subject to approval by its board.
Does Agilent buy back its own shares?: Yes. In fiscal 2025 it repurchased 3.0 million shares for $374 million under its 2023 program and 381,670 shares for $51 million under its 2024 program, excluding excise taxes (10-K). At July 31, 2026 it had remaining authorization of approximately $1,654 million (10-Q).
Who runs Agilent?: Padraig McDonnell has served as President and Chief Executive Officer since May 2024, and Adam S. Elinoff has been Chief Financial Officer since November 2025, according to its 10-K for fiscal 2025.